Treats progressive, metastatic medullary thyroid cancer (MTC). Sold as Cometriq, Cabometyx. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 16, 2026, FDA lists 4 applications for Cabozantinib S-Malate (sold as Cometriq, Cabometyx), first approved Nov 29, 2012, with 8 new uses approved and 0 published complete response letters.
| Cabometyx | Part D | $1.54B | +27% | 11,335 |
| Cometriq | Part D | $4.8M | +43% | 67 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialAdvanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma · National Cancer Institute (NCI) | Phase 1 / Phase 2 | Recruiting | Feb 6, 2025 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerLocally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma · Emory University | Phase 2 | Recruiting | Aug 23, 2023 |
| Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialMetastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jun 9, 2022 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma · University of Utah | Phase 2 | Active, not recruiting | Dec 23, 2021 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · National Cancer Institute (NCI) | Phase 2 | Recruiting | Nov 29, 2021 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerAdvanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma · City of Hope Medical Center | Phase 1 | Active, not recruiting | Nov 16, 2021 |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryAnal Melanoma, Bladder Melanoma · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Nov 8, 2021 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyAdvanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma · National Cancer Institute (NCI) | Phase 3 | Active, not recruiting | Oct 26, 2021 |
| Nov 29, 2012 | CometriqNDA 203756 · New molecular entity | Exelixis | 8 | Marketed |
| Apr 25, 2016 | CabometyxNDA 208692 · New dosage form | Exelixis Inc | 14 | Marketed |
| Aug 14, 2026 | Cabozantinib S-MalateANDA 213878 | Msn | 0 | Marketed |
| Oct 16, 2026 | Cabozantinib S-MalateANDA 217870 | Cipla | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA